Deborah A Lewinsohn1, Mark N Lobato, John A Jereb. 1. Division of Infectious Disease, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239, USA. lewinsde@ohsu.edu
Abstract
PURPOSE OF REVIEW: The testing and treatment of children at risk for Mycobacterium tuberculosis infection represents an important public health priority in the United States. Until recently, diagnosis has relied upon the tuberculin skin test (TST). New interferon-gamma release assays (IGRAs) offer improvements over TST, but these tests have not been studied in children until recently. RECENT FINDINGS: Evidence regarding IGRA performance in children is accumulating rapidly. Overall, the findings demonstrate performance of IGRAs equivalent or superior to that of the TST. However, IGRAs have biological limitations similar to TST and some technical problems of their own, and critical gaps in our knowledge remain. SUMMARY: Current evidence supports usage of IGRAs in children aged 5 years or older. IGRAs are preferred over TST when specificity is paramount or wherein patients might fail to return for TST reading. Evidence for use in children aged less than 5 years is insufficient at this time: the sensitivity is poorly defined, and TST is preferred for testing these children. Future IGRA research should focus on children aged less than 5 years for informing expanded usage in this vulnerable population.
PURPOSE OF REVIEW: The testing and treatment of children at risk for Mycobacterium tuberculosis infection represents an important public health priority in the United States. Until recently, diagnosis has relied upon the tuberculin skin test (TST). New interferon-gamma release assays (IGRAs) offer improvements over TST, but these tests have not been studied in children until recently. RECENT FINDINGS: Evidence regarding IGRA performance in children is accumulating rapidly. Overall, the findings demonstrate performance of IGRAs equivalent or superior to that of the TST. However, IGRAs have biological limitations similar to TST and some technical problems of their own, and critical gaps in our knowledge remain. SUMMARY: Current evidence supports usage of IGRAs in children aged 5 years or older. IGRAs are preferred over TST when specificity is paramount or wherein patients might fail to return for TST reading. Evidence for use in children aged less than 5 years is insufficient at this time: the sensitivity is poorly defined, and TST is preferred for testing these children. Future IGRA research should focus on children aged less than 5 years for informing expanded usage in this vulnerable population.
Authors: E Chiappini; A Lo Vecchio; S Garazzino; G L Marseglia; F Bernardi; E Castagnola; P Tomà; D Cirillo; C Russo; C Gabiano; D Ciofi; G Losurdo; M Bocchino; E Tortoli; M Tadolini; A Villani; A Guarino; S Esposito Journal: Eur J Clin Microbiol Infect Dis Date: 2016-01 Impact factor: 3.267
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: N Shaikh; A Gupte; S Dharmshale; S Pokkali; M Thakar; V J Upadhye; A A Ordonez; A Kinikar; N Gupte; V Mave; A Kagal; A Gupta; A Lalvani; R Paranjpe; R Bharadwaj; S K Jain Journal: Int J Tuberc Lung Dis Date: 2017-04-01 Impact factor: 2.373
Authors: Benjamin L Laskin; Jens Goebel; Jeffrey R Starke; Daniel P Schauer; Mark H Eckman Journal: Am J Kidney Dis Date: 2012-07-10 Impact factor: 8.860
Authors: Roi Piñeiro; María José Mellado; María José Cilleruelo; Marta García-Ascaso; Antonio Medina-Claros; Milagros García-Hortelano Journal: Eur J Pediatr Date: 2012-07-01 Impact factor: 3.183
Authors: Michala V Rose; Godfather Kimaro; Thomas N Nissen; Inge Kroidl; Michael Hoelscher; Ib C Bygbjerg; Sayoki G Mfinanga; Pernille Ravn Journal: PLoS One Date: 2012-07-12 Impact factor: 3.240